Report cover image

Wegener Vasculitis Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147091

Description

Wegener's vasculitis, also known as Granulomatosis with Polyangiitis (GPA), is a rare autoimmune disease that primarily affects small and medium-sized blood vessels. The annual incidence is approximately 8-10 cases per million, with the prevalence estimated to be around 3 cases per 100,000 people. The disease accounts for a significant portion of vasculitic disorders, with a notable impact on kidney, lung, and upper respiratory tract function. There is a high unmet clinical need for better therapies to treat Wegener's Vasculitis, as current treatment options, such as corticosteroids and immunosuppressive agents, often lead to significant side effects. Further, the growing focus on targeted biologic therapies, personalized medicine, and advancements in immunotherapy are likely to support pipeline growth in the coming years, offering hope for improved management and outcomes for patients.

Report Coverage

The Wegener Vasculitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into Wegener vasculitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Wegener vasculitis. The Wegener vasculitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Wegener vasculitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with Wegener vasculitis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Wegener vasculitis.

Wegener Vasculitis Drug Pipeline Outlook

Wegener’s vasculitis, now known as granulomatosis with polyangiitis (GPA), is a rare but serious autoimmune disorder that causes inflammation of small- and medium-sized blood vessels. It primarily affects the kidneys, lungs, and upper respiratory tract. In this condition, the body's immune system mistakenly targets and attacks the blood vessels, leading to damage, decreased blood flow, and impaired organ function. While the exact cause is unknown, genetic predisposition and environmental triggers like infections are believed to play a role in its development.

Wegener vasculitis treatment generally involves a combination of medications to suppress the overactive immune system and reduce inflammation. High-dose corticosteroids, such as prednisone, are commonly used in the initial phase, often alongside cyclophosphamide or rituximab to target and reduce disease activity. Once the disease is under control, maintenance therapy may include methotrexate or azathioprine to prevent relapse. Frequent monitoring of organ function and side effects is crucial to ensure optimal outcomes and minimize complications.

Wegener Vasculitis – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of Wegener Vasculitis drug candidates based on several segmentations including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Monoclonal Antibodies
  • Gene Therapies
By Route of Administration
  • Oral
  • Parenteral
  • Others
Wegener Vasculitis – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total Wegener vasculitis clinical trials.

Wegener Vasculitis – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the Wegener vasculitis pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Wegener vasculitis.

Wegener Vasculitis Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the Wegener Vasculitis report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Wegener vasculitis clinical trials:
  • GlaxoSmithKline
  • Guangdong Hengrui Pharmaceutical Co.
  • Ltd, AstraZeneca
  • Sana Biotechnology
  • Alpine Immune Sciences, Inc.
  • Hoffmann-La Roche
  • Nippon Kayaku Co., Ltd.
  • Essen Biotech
Wegener Vasculitis Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for Wegener vasculitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Wegener vasculitis drug candidates.

5 mg prednisone

Sponsored by the NIH, the drug is currently under evaluation in a Phase 3 study. The objective of this study is to evaluate the impact of low-dose prednisone (5 mg/day) versus complete cessation (0 mg/day) on disease relapse rates in patients with remission from granulomatosis with polyangiitis (GPA). With 12 participants enrolled, the study is expected to be completed by December 2025.

NS-229

The drug is under investigation in a Phase 2 study, sponsored by NS Pharma, Inc., that is designed to assess the safety and efficacy of NS-229 versus placebo in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). The study will enroll approximately 45 participants and span 28 weeks. The main objective is to achieve clinical remission, defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 with a corticosteroid dose of ≤4 mg/day. The trial is expected to be completed by July 2026.

Reasons To Buy This Report

The Wegener Vasculitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Wegener vasculitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within Wegener vasculitis pipeline insights.

Key Questions Answered in the Wegener Vasculitis Pipeline Insight Report
  • What is the current landscape of Wegener vasculitis pipeline drugs?
  • How many companies are developing Wegener vasculitis drugs?
  • How many phase III, and phase IV drugs are currently present in Wegener vasculitis pipeline drugs?
  • Which companies/institutions are leading the Wegener vasculitis drug development?
  • What is the efficacy and safety profile of Wegener vasculitis pipeline drugs?
  • What are the opportunities and challenges present in the Wegener vasculitis drug pipeline landscape?
  • Which company is conducting major trials for Wegener vasculitis drugs?
  • What geographies are covered for Wegener vasculitis clinical trials?
  • What are emerging trends in Wegener vasculitis clinical trials?
Related Reports

Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Wegener Vasculitis
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Wegener Vasculitis
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Wegener Vasculitis: Epidemiology Snapshot
5.1 Wegener Vasculitis Incidence by Key Markets
5.2 Wegener Vasculitis – Patients Seeking Treatment in Key Markets
6 Wegener Vasculitis: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Wegener Vasculitis: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Wegener Vasculitis, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Wegener Vasculitis Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Wegener Vasculitis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: 5 mg prednisone
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: Hydroxychloroquine, Mepolizumab
10.2.3 BIOLOGICAL: Depemokimab, Benralizumab
10.2.4 Other Drugs
11 Wegener Vasculitis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Rituximab
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Tocilizumab
11.2.3 Abatacept
11.2.4 NS-229
11.2.5 Other Drugs
12 Wegener Vasculitis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: AB-101
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Drug: Cyclophosphamide, Fludarabine
12.2.3 Biological: SC291
12.2.4 Other Drugs
13 Wegener Vasculitis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Wegener Vasculitis, Key Drug Pipeline Companies
14.1 GlaxoSmithKline
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Guangdong Hengrui Pharmaceutical Co
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 AstraZeneca
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Sana Biotechnology
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Alpine Immune Sciences, Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Hoffmann-La Roche
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Nippon Kayaku Co., Ltd.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Essen Biotech
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us